Drugs / LUM-201
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 25 trials | ||||||
| Phase 2 | NCT05796440 | Aug 2023 → Mar 2028 expected | pituitary deficiency | Lumos Pharma | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT05364684 | Aug 2022 → Nov 2024 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05250063 | Feb 2022 → Jan 2025 | pituitary deficiency | Lumos Pharma | Completed | No outcome recorded |
| Phase 2 | NCT04806854 | Jul 2021 → Apr 2030 expected | pituitary deficiency | Lumos Pharma | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04614337 | Dec 2020 → Sep 2024 | pituitary deficiency | Lumos Pharma | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07129759 | Feb 2027 → Feb 2030 expected | pituitary deficiency | Lumos Pharma | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06948214 | May 2026 → Dec 2027 expected | pituitary deficiency | Lumos Pharma | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUM-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06948214 ↗ |
| Route | Oral | “Administered orally once daily” NCT04614337 ↗ |